HLN Company Profile and Key Details

Haleon plc generated EPS of $0.43 over the past year. Five-year average earnings growth is 17.4%. Wall Street analysts project EPS growth of 9.26% annually over the next five years. The latest quarter delivered EPS of $0.14. The next quarter is forecast at $0.13. Next year's EPS is expected at $7.78. Haleon plc earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by -42.83%. The prior quarter beat by -67.33%. Over the last six quarters, Apple has recorded several small beats. These include 9300.0% in May 01, 2024.

Short-term trend indicators are bearishly aligned (SMA20 -1.32%, SMA50 3.52%, SMA200 7.98%). The stock’s 14-day RSI is 50.32 (neutral), while the ATR of 0.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.78% below its high and over 23.54% above its low. Average 10-day trading volume of 5.48 million shares is below the 3-month average of 8.29 million, indicating normal recent market interest.

Haleon plc has 4.48 billion shares outstanding. The public float is 8.95 billion shares, elevated short interest at 0.39% of float. This equals 17.45 million shares. The short ratio is 1.39 days. Institutional investors hold 12.85% of the float. Insiders own 0.02%.

Haleon plc last paid a dividend of 0.3 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $22.62. This means the shares are trading below this model’s fair value.

Haleon plc (NYSE:HLN) closed at $9.59 USD, losing -$0.07 (-0.72%) from the previous close of $9.66. The stock is currently mid-range between its 52-week high and low $8.71 and $11.42. With a market capitalization of about $42.74 billion, Haleon plc is classified as a large-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 8.42 million shares, volume is running light vs its 52-week average. Headquartered in Weybridge, None, Haleon plc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Brian James McNamara, the company employs approximately 24,561 people and listed since July 25, 2022. Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

Our AI price prediction model suggests that Haleon plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.41%, with price expected at $9.66 by April 28, 2026, within a range of $9.43 to $9.88 3-Month Outlook: Projected rise of 7.53%, reaching $10.43 by July 13, 2026, with a range of $10.06 to $10.79. 1-Year Outlook: Projected gain of 123.4%, with price at $21.67 by April 14, 2027, within a range of $11.55 to $31.44.

Haleon plc (NYSE:HLN) shares are flat 0.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Haleon plc trading at a premium to the broader market with a P/E of 11.49. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $10.47, suggesting 7.94% upside. Our AI forecast model points to short-term weakness (-0.41% over two weeks), a medium-term rise (7.53% over three months), and a longer-term gain (123.4% over one year), with expected trading ranges indicating moderate volatility.

Haleon plc trades at a P/E ratio of 11.49, slightly below the S&P 500 average, with a price-to-sales ratio of 1.66 and a price-to-book ratio of 1.95 suggesting the stock is closer to book value. The P/FCF stands at 13.97, also below market averages.